Helix BioPharma Co.

Toronto, Ontario – TheNewswire – April 24, 2025 - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointments of Veronika Kandziora as Chief Operating Officer ( “COO” ) and Jessica Kourniaktis, DPhil , as Director of Communications of the Company.   Ms. Kandziora is a seasoned executive with over 20 years of leadership experience across the biopharma, financial, and consulting sectors, bringing a rare trifecta of administrative acumen, people-centered leadership, and organizational insight to her role as COO of Helix BioPharma. Her long-standing relationship with the Company brings invaluable continuity and deep institutional knowledge to this role, having supported corporate strategy, transformation, and stakeholder engagement for Helix in Europe and North America. She previously served as Corporate Secretary of Helix (2017–2019) and as a strategic consultant to the Company's leadership and Board in the years leading up to her appointment. Alongside these roles, she spent 15 years as an independent Asset Manager, advising clients on corporate development, intellectual property, and strategic investments—primarily in the biopharma space. Ms. Kandziora began her career in the financial industry in 2003, leading complex international projects across Germany, Austria, Italy, and Liechtenstein, and consulting for wealth managers, trustees, and investment funds with a focus on biotechnology, technology, and raw materials. A polyglot with a strong foundation in finance and compliance, Ms. Kandziora holds a Diploma in Management and Hospitality from the WIFI Academy of Applied Sciences in Austria, and is a certified Vocational Trainer in Liechtenstein. She has also completed advanced compliance training with the Institute for Compliance and Quality Management (ICQM) and the Association for Quality Assurance of Financial Services (VQF), reinforcing her ability to navigate complex regulatory and governance environments with confidence and clarity.» Mehr auf thenewswire.com

April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointment of Thomas Mehrling, MD, PhD as Chief Executive Officer ( “CEO” ) of the Company. A sharpening of Helix's leadership structure, outgoing CEO, Jacek Antas , will dedicate his focus to his role as Chairman of the Company, and Dr. Mehrling, who has shaped Helix's clinical strategy in his capacity as Chief Medical Officer ( “CMO” ), takes the helm to deliver on the Company's ambitious clinical milestones planned for 2025 and beyond.   A distinguished Hemato-Oncologist and Pharmacologist with over 20 years of experience in pharmaceutical oncology, Dr. Mehrling has a proven track record of building successful, global oncology businesses and delivering transformative therapies to the market. As a key architect of Mundipharma International Ltd.'s European oncology business, Dr. Mehrling served as Head of Business Development (2000–2004), European Director of Oncology (2004-2011), and International Director of Oncology Strategy (2011-2013), introducing groundbreaking cancer drugs across Europe that achieved sales nearing USD 1 billion (DepoCyte® and Levact®, Ribomustin® and Treanda®). In 2013, he led the establishment and took the helm of Mundipharma EDO GmbH, a Swiss-based start-up within the Mundipharma Group dedicated to the development of highly selective inhibitors and targeted medicines for hematological malignancies and solid tumors. In 2019, he founded Laevoroc Medical AG, a privately held, Swiss oncology company, whose asset acquisition by Helix laid the foundations for a broader strategic collaboration between Dr. Mehrling and the Company. Prior to his tenure at Mundipharma, Dr. Mehrling served as Senior Vice President of global CRO Medical Affairs at Staticon International, and as Medical Leader at Takeda European R&D Center. Before his transition to the pharmaceutical industry, Dr. Mehrling spent 13 years as an MD at the University Hospital in Frankfurt, where he earned his MD degree from the Department of Internal Medicine (Hemato-oncology and Cardiology) and his PhD in Pharmacology.» Mehr auf thenewswire.com

April 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that, subject to regulatory approval, it has engaged the services of Independent Trading Group ( "ITG" ) to provide market-making services in accordance with Toronto Stock Exchange ( “TSX” ) policies. ITG will trade shares of the Company on the TSX and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares.   Under the agreement, ITG will receive a monthly compensation, payable in advance. The agreement is for an initial term of one month and will renew for additional one-month terms unless terminated. The agreement may be terminated by either party with 30 days' notice. There are no performance factors contained in the agreement and ITG will not receive shares or options as compensation. ITG and the Company are unrelated and unaffiliated entities and at the time of the agreement, neither ITG nor its principals have an interest, directly or indirectly, in the securities of the Company .» Mehr auf thenewswire.com